Bemcentinib (R428) Mechanism of Action: AXL Inhibition in Tumor Cell Research

Bemcentinib (R428) MOA:Targeting AXL/PI3K-AKT Pathway for Non-Small Cell Lung Cancer

🎯 check Bemcentinib (R428) product page

Bemcentinib (R428) is a highly selective and potent AXL inhibitor. It affects PI3K/AKT, NF-κB, and STAT signaling pathways by blocking AXL phosphorylation, thereby inhibiting tumor proliferation, migration, and inflammation, and promoting apoptosis.

Primary Applications and Mechanism of Action